Document is current

Article History

Received: 25 November 2023

Accepted: 20 March 2024

First Online: 9 April 2024

Declarations

:

: The study is approved by the Institutional Review Board (IRB) of the H. Lee Moffitt Cancer Center and Research Institute (Moffitt IRB #21136). Subjects consent to participate after thorough discussion by signing of the IRB approved informed consent document. If any major amendments are made, subjects will be given the opportunity to re-consent after a full disclosure by the principal investigator and the clinical research coordinator.

: This manuscript does not include identifying details, images, or videos relating to an individual person.

: Full disclosures include: Dr. Eschrich and Dr. Torres-Roca are co-founders, board members, and stockholders of Cvergenx, a genomics radiation informatics company. They, along with Dr. Scott, who is a stockholder, own intellectual property involved in this trial (i.e., RSI and GARD). Dr. Scott was also supported by NIH grants R37 CA244613 and 5U54CA274513-02 (Radiation Oncology Biology Integration Network), and a Research Scholar Grant from the American Cancer Society. Drs. Arash Naghavi and Stephen Rosenberg have received research grants from ViewRay, outside the scope of the submitted work. Dr. Rosenberg has also received an honorarium, served on the Lung Research Consortium Advisory Board for ViewRay, and performed consulting for Viewray, Novocure, and GE Healthcare. Drs. Vladimir Feygelman and Kujtim Latifi have received consulting fees from ViewRay. Dr. Ahmed has research funding to the institution from Eli Lilly, Gilead, and Genentech, and serves on the advisory board of Castle Biosciences. No other author has any conflict of interest to declare.